Moody Aldrich Partners LLC Sells 60,990 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Moody Aldrich Partners LLC lowered its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 22.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 215,657 shares of the biopharmaceutical company’s stock after selling 60,990 shares during the period. Moody Aldrich Partners LLC owned about 0.18% of Catalyst Pharmaceuticals worth $4,501,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. GAMMA Investing LLC lifted its stake in Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 681 shares during the period. nVerses Capital LLC bought a new stake in Catalyst Pharmaceuticals during the 3rd quarter valued at approximately $50,000. Larson Financial Group LLC grew its holdings in shares of Catalyst Pharmaceuticals by 27,218.2% during the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 2,994 shares during the period. KBC Group NV raised its position in shares of Catalyst Pharmaceuticals by 48.8% in the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 1,542 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. purchased a new stake in Catalyst Pharmaceuticals in the fourth quarter worth $134,000. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Stock Up 0.6 %

Shares of CPRX opened at $22.84 on Wednesday. The business has a 50-day simple moving average of $21.86 and a two-hundred day simple moving average of $20.61. The stock has a market cap of $2.72 billion, a price-to-earnings ratio of 19.36, a PEG ratio of 2.28 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a 52 week low of $13.12 and a 52 week high of $24.27.

Analyst Ratings Changes

Several equities analysts have commented on CPRX shares. StockNews.com lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 11th. Bank of America reiterated a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. HC Wainwright raised their price objective on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Stephens began coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an “overweight” rating and a $35.00 price objective for the company. Finally, Truist Financial increased their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $32.86.

Insider Activity at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 12,000 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total transaction of $272,640.00. Following the completion of the transaction, the insider now directly owns 51,391 shares of the company’s stock, valued at approximately $1,167,603.52. This represents a 18.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Molly Harper sold 17,500 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 79,500 shares of company stock valued at $1,754,140. 11.00% of the stock is owned by company insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.